Insights

Gathering insights about Apto…

Similar companies to Apto

Apto Tech Stack

Apto uses 8 technology products and services including Criteo, Hotjar, TikTok Pixel, and more. Explore Apto's tech stack below.

Criteo
Advertising
Hotjar
Analytics
TikTok Pixel
Analytics
cdnjs
Content Delivery Network
Open Graph
Content Management System
Cloudflare
Content Management System
Google Fonts API
Font Scripts
Goober
Javascript Libraries

Media & News

Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
Dec 06, 2025 | www.globenewswire.com
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO) crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.89 and traded as high as C$2.32. Aptose Biosciences shares last traded at C$2.32, with a volume of 4,636 shares. Analyst Ratings Changes Separately, Alliance
Dec 03, 2025 | www.defenseworld.net
Aptose Announces Auditor Not Standing for Re-Appointment
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025.
Apr 23, 2025 | www.globenewswire.com
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G.
Apr 23, 2025 | www.globenewswire.com
Aptose Reports Year End 2024 Results and Corporate Highlights
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update. "During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML),” said William G.
Mar 28, 2025 | www.globenewswire.com
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is in compliance with Nasdaq's minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company's common shares has been $1.00 per share or greater.
Mar 17, 2025 | www.globenewswire.com
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Feb 20, 2025 | www.benzinga.com

Apto's Email Address Formats

Apto uses at least 1 format(s):

Apto Email Formats	Example	Percentage
First.Last@apto.vc	John.Doe@apto.vc	50%
First.Last@apto.vc	John.Doe@apto.vc	50%

Frequently Asked Questions

What is Apto's stock symbol?

Apto is a publicly traded company; the company's stock symbol is APTO.

What is Apto's official website and social media links?

Apto's official website is apto.vc and has social profiles on LinkedIn.

What is Apto's SIC code NAICS code?

Apto's SIC code is 4899 - Communications Services, Not Elsewhere Classified NAICS code is 425 - Wholesale Electronic Markets and Agents and Brokers.

How many employees does Apto have currently?

As of December 2025, Apto has approximately 33 employees across 4 continents, including South AmericaEuropeAsia. Key team members include Founder & Ceo: A. F.Growth Marketing Manager: A. R.Customer Success Manager: M. L.. Explore Apto's employee directory with LeadIQ.

What industry does Apto belong to?

Apto operates in the Internet Marketplace Platforms industry.

What technology does Apto use?

Apto's tech stack includes CriteoHotjarTikTok PixelcdnjsOpen GraphCloudflareGoogle Fonts APIGoober.

What is Apto's email format?

Apto's email format typically follows the pattern of First.Last@apto.vc. Find more Apto email formats with LeadIQ.

When was Apto founded?

Apto was founded in 2015.

Apto

Q: What is Apto's official website and social media links?

Apto's official website is apto.vc. Apto has social profiles on LinkedIn.

Q: How many employees does Apto have currently?

Apto has approximately 33 employees.

Q: What technology does Apto use?

Apto's tech stack includes Google Conversion Tracking, reCAPTCHA, React, Radix UI, Modernizr.

Internet Marketplace PlatformsSão Paulo, Brazil11-50 Employees

Apto is a platform that integrates everyone interested in real estate launches, including property buyers, construction companies, developers, real estate agencies, digital native brokers, agencies and CRMs. The proposal is to innovate by delivering autonomy to our customers through more intuitive campaigns, innovative digital products and personalized service.